Displaying drugs 851 - 875 of 12697 in total
Chlorphenesin
Approved
Experimental
Sacituzumab govitecan
Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited ... [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent ... Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of …
Remestemcel-L
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … is often characterized by the presence of inflammatory cascades through signalling of activated T cells ... Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal ... to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022]. …
Human interferon beta
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis ... disease that is usually progressive and significantly debilitating with a profound impact on the quality of …
Drotaverine
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... [A231614] More recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia ... Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal …
Nonacog beta pegol
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Ferric maltol
Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Strontium chloride
Strontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. This kind of barrier protection for tooth hypersensitivity has, however, been...
Approved
Matched Description: … Strontium chloride (SrCl2) is a salt of strontium and chloride. ... chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of ... This kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste …
Danaparoid
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … of a mixture of glycosaminoglycans [A32565]. ... and prevention of post-operative deep venous thrombosis (DVT). ... Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting …
Human vaccinia virus immune globulin
Human vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine who possess high titers of anti-vaccinia virus antibody [FDA Label, A33814]. The IgG fraction is purified by the anion-exchange column chromatography...
Approved
Matched Description: … from healthy donors previously vaccinated with live vaccinia virus vaccine who possess high titers of ... vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of ... Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human …
Relugolix
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … treatment of prostate cancer. ... [L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. ... Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several …
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast ... [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... [A254387]
The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes …
Cyproheptadine
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Description: … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. ... perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of …
Butylscopolamine
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic …
Parathyroid hormone
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids...
Approved
Investigational
Matched Description: … Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic ... Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. ... Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion …
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... A study was performed on the pharmacokinetics of this drug on various ethnicities. ... high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … treatment with a minimum of 3 other kinase inhibitors. ... Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST ... [L13769]
It is the first drug approved as a fourth-line therapy in the specific setting of prior …
Icodextrin
Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport...
Approved
Investigational
Matched Description: … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal …
Solriamfetol
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators ... This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single ... autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... of this debilitating disorder. ... The most common subtype of MoCD, type A, involves mutations in _MOCS1_ wherein the first step of molybdenum …
Exenatide
Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA approval on April 28, 2005 . It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand...
Approved
Investigational
Matched Description: … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension …
Vericiguat
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst...
Approved
Investigational
Matched Description: … Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic ... [L31153] A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular ... enzymes found in vascular smooth muscle cells (amongst other cell types) that catalyze the synthesis of …
Dostarlimab
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … cancers, including those of the skin, lung, kidneys, and liver. ... [L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours ... accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of …
Displaying drugs 851 - 875 of 12697 in total